Summary
ProVerum Limited, an innovative Dublin based SME focused on the development of novel minimally invasive technologies to treat Benign Prostatic Hyperplasia, a common condition in older men causing difficulty with urination with a profound deterioration in quality of life.
The company’s first product (called ‘ProVee’) is a self-expanding implant that alleviates the symptoms caused by BPH.
Benign Prostatic Hyperplasia is an enlargement of the prostate gland which causes impingement upon the urethra, the tube which eliminates urine from the bladder. Sufferers present with Lower Urinary Tract Symptoms (LUTS), including difficulty in urinating and urinary retention causing a frequent urge to urinate day and night and having a profound effect on quality of life.
BPH is extremely common in men and is the number 1 reason men visit their urologist both in the US and Europe, with 19M men treated for BPH each year in Europe and 12M men treated for BPH each year in the US.
ProVee offers the patient relief from BPH symptoms through a simple, minimally invasive, 5-minute, outpatient procedure to implant the ProVee device under local anaesthetic. Once implanted, the ProVee addresses urinary problems, is well tolerated and early data suggests has an excellent safety profile
Following this H2020 EIC Accelerator project, the technology will be at TRL 8, with clinical evidence from a 50 Patient CE Trial, CE Mark approval and further commercialisation will enable the treatment of 70,000 patients in Year 4 post project.
The company’s first product (called ‘ProVee’) is a self-expanding implant that alleviates the symptoms caused by BPH.
Benign Prostatic Hyperplasia is an enlargement of the prostate gland which causes impingement upon the urethra, the tube which eliminates urine from the bladder. Sufferers present with Lower Urinary Tract Symptoms (LUTS), including difficulty in urinating and urinary retention causing a frequent urge to urinate day and night and having a profound effect on quality of life.
BPH is extremely common in men and is the number 1 reason men visit their urologist both in the US and Europe, with 19M men treated for BPH each year in Europe and 12M men treated for BPH each year in the US.
ProVee offers the patient relief from BPH symptoms through a simple, minimally invasive, 5-minute, outpatient procedure to implant the ProVee device under local anaesthetic. Once implanted, the ProVee addresses urinary problems, is well tolerated and early data suggests has an excellent safety profile
Following this H2020 EIC Accelerator project, the technology will be at TRL 8, with clinical evidence from a 50 Patient CE Trial, CE Mark approval and further commercialisation will enable the treatment of 70,000 patients in Year 4 post project.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/954555 |
| Start date: | 01-05-2020 |
| End date: | 30-04-2022 |
| Total budget - Public funding: | 3 750 635,00 Euro - 2 499 999,00 Euro |
Cordis data
Original description
ProVerum Limited, an innovative Dublin based SME focused on the development of novel minimally invasive technologies to treat Benign Prostatic Hyperplasia, a common condition in older men causing difficulty with urination with a profound deterioration in quality of life.The company’s first product (called ‘ProVee’) is a self-expanding implant that alleviates the symptoms caused by BPH.
Benign Prostatic Hyperplasia is an enlargement of the prostate gland which causes impingement upon the urethra, the tube which eliminates urine from the bladder. Sufferers present with Lower Urinary Tract Symptoms (LUTS), including difficulty in urinating and urinary retention causing a frequent urge to urinate day and night and having a profound effect on quality of life.
BPH is extremely common in men and is the number 1 reason men visit their urologist both in the US and Europe, with 19M men treated for BPH each year in Europe and 12M men treated for BPH each year in the US.
ProVee offers the patient relief from BPH symptoms through a simple, minimally invasive, 5-minute, outpatient procedure to implant the ProVee device under local anaesthetic. Once implanted, the ProVee addresses urinary problems, is well tolerated and early data suggests has an excellent safety profile
Following this H2020 EIC Accelerator project, the technology will be at TRL 8, with clinical evidence from a 50 Patient CE Trial, CE Mark approval and further commercialisation will enable the treatment of 70,000 patients in Year 4 post project.
Status
CLOSEDCall topic
EIC-SMEInst-2018-2020Update Date
27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
EU-Programme-Call
